Teachers Retirement System of The State of Kentucky Boosts Stake in Vaxcyte, Inc. (NASDAQ:PCVX)

Key Points

• The Teachers Retirement System of The State of Kentucky increased its holdings in Vaxcyte, Inc. by 36.8%, acquiring an additional 6,929 shares, bringing its total ownership to 25,760 shares valued at approximately $973,000.
• Vaxcyte's stock has an average rating of "Buy" from nine research analysts, with a consensus price target of $136.50, despite a recent earnings report that showed a loss greater than analysts' expectations.
• The company focuses on developing innovative vaccines to combat bacterial infectious diseases, with its leading candidate being VAX-24, aimed at preventing invasive pneumococcal disease.

Teachers Retirement System of The State of Kentucky lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 36.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,760 shares of the company's stock after buying an additional 6,929 shares during the period. Teachers Retirement System of The State of Kentucky's holdings in Vaxcyte were worth $973,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PCVX. Bridgefront Capital LLC raised its holdings in shares of Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after acquiring an additional 172 shares during the period. Nisa Investment Advisors LLC raised its stake in Vaxcyte by 10.9% during the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock worth $112,000 after purchasing an additional 293 shares during the period. Avior Wealth Management LLC boosted its holdings in Vaxcyte by 5.3% in the 1st quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock valued at $257,000 after purchasing an additional 343 shares during the last quarter. Xponance Inc. grew its stake in shares of Vaxcyte by 4.7% in the 1st quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after buying an additional 415 shares during the period. Finally, National Bank of Canada FI purchased a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $41,000. Institutional investors and hedge funds own 96.78% of the company's stock.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $0.44 during trading on Monday, hitting $36.20. The company's stock had a trading volume of 562,702 shares, compared to its average volume of 1,815,275. The company has a market capitalization of $4.67 billion, a PE ratio of -9.11 and a beta of 1.19. The business has a 50 day moving average price of $34.38 and a two-hundred day moving average price of $51.77. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the prior year, the firm posted ($0.85) EPS. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PCVX. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price target on shares of Vaxcyte in a research report on Tuesday, April 8th. The Goldman Sachs Group lowered their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Bank of America reduced their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI raised shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, Cantor Fitzgerald began coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.